Gilead Sciences, Inc. vs Alphabet Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $133.08 (market cap $163.51B), while Alphabet Inc Class A trades at $372.74 (market cap $4.52T). The key difference: Alphabet Inc Class A is far larger — about 27.6× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | GOOGL | |
|---|---|---|
Market Cap | $163.51B | $4.52T |
Sector | Health | Media |
52-Week High | $155.80 | $402.62 |
52-Week Low | $108.22 | $182.97 |
Enterprise Value | $178.05B | $4.49T |
Dividend Yield | 2.49% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Alphabet (GOOGL) trades at $359.51, up 1.99% on the day, with a neutral technical signal but bullish moving averages. The company demonstrates strong fundamentals with revenue growing to $402.84B in 2025 and net income surging to $132.17B, yielding a 32.8% profit margin. Recent earnings have consistently beaten expectations, and the company initiated its first dividend. Analyst sentiment remains overwhelmingly positive with an 85% buy rating and a $431.78 consensus price target, suggesting significant upside potential from current levels.
The outlook for GOOGL is positive, driven by robust earnings growth, expanding AI integration across its ecosystem, and strong cash flow generation. Key opportunities include leadership in AI infrastructure, monetization of YouTube and cloud services, and strategic investments like SpaceX. Primary risks involve regulatory scrutiny, intense competition in AI and cloud computing, and potential market volatility. The stock's current valuation, while elevated, is supported by its growth trajectory and dominant market position.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →